Silvercrest Asset Management Group LLC Intra Cellular Therapies, Inc. Transaction History

Silvercrest Asset Management Group LLC

$14.3 Billion
Q3 2024

A detailed history of Silvercrest Asset Management Group LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 118,848 shares of ITCI stock, worth $10.2 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

118,848

Previous 119,570 0.6%

Holding current value

$10.2 Million

Previous $8.19 Million 6.12%

% of portfolio

0.06%

Previous 0.06%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$67.99 - $80.84 $49,088 - $58,366	-722 Reduced 0.6%	118,848 $8.69 Million
Q2 2024 Aug 14, 2024	SELL	$64.76 - $79.84 $7.74 Million - $9.55 Million	-119,570 Reduced 50.0%	119,570 $8.19 Million
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $12.7 Million - $15.7 Million	196,864 Added 465.66%	239,140 $16.4 Million
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $869,445 - $1.02 Million	-13,507 Reduced 24.21%	42,276 $2.93 Million
Q4 2023 Feb 14, 2024	SELL	$46.37 - $73.65 $1.05 Million - $1.66 Million	-22,591 Reduced 28.82%	55,783 $4 Million
Q3 2023 Nov 14, 2023	SELL	$52.09 - $64.1 $3,646 - $4,487	-70 Reduced 0.09%	78,374 $4.08 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $641,060 - $779,075	11,726 Added 17.58%	78,444 $4.97 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $1.39 Million - $1.81 Million	-31,756 Reduced 32.25%	66,718 $3.61 Million
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $64,165 - $79,279	-1,456 Reduced 1.46%	98,474 $5.21 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $106,066 - $149,015	-2,484 Reduced 2.43%	99,930 $4.65 Million
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $233,232 - $356,031	-5,424 Reduced 5.03%	102,414 $5.85 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $49,548 - $79,413	1,279 Added 1.2%	107,838 $6.6 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $2.14 Million - $3.25 Million	-60,752 Reduced 36.31%	106,559 $5.58 Million
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $77,055 - $114,000	-2,683 Reduced 1.58%	167,311 $6.24 Million
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $9,932 - $15,085	-339 Reduced 0.2%	169,994 $6.94 Million
Q1 2021 May 17, 2021	SELL	$30.8 - $39.51 $662,723 - $850,136	-21,517 Reduced 11.22%	170,333 $5.78 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $4.48 Million - $6.18 Million	191,850 New	191,850 $6.1 Million

Others Institutions Holding ITCI

# of Institutions

377

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.08B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.

Account

Silvercrest Asset Management Group LLC Intra Cellular Therapies, Inc. Transaction History